CentriMag System with New ECMO Indication | Abbott
CARDIOVASCULAR
hamburger
BACK
THE CENTRIMAG ACUTE CIRCULATORY SUPPORT SYSTEM


The Only Acute Device Approved As A 30-Day VAD* – Is Now Cleared For ECMO***

With the addition of the new ECMO indication for the CentriMag™ Blood Pump, the CentriMag™ System addresses the broadest spectrum of clinical challenges in a single platform allowing for escalation and de‑escalation of therapy1-3

CentriMag Pump Outline indicating LVAD, RVAD, ECMO and BiVAD in four sections.

Powered By Full Maglev™ Flow Technology, The Centrimag Pump Enables Excellent Hemodynamics4,5 And Optimal Clinical Outcomes1

CentriMag System shows 66% high survival rate at discharge after ECMO, 2.5% low device-related thrombosis, 5% low hemolysis and minimized blood stagnation, friction, and sheer stress.

See The Centrimag Pump In Action

Our Reliability Is Backed By Our Unmatched Legacy Of Experience

Four
Our device is proven safe by four FDA-approved clinical studies*

400
Our device has been cited in over 400 peer-reviewed articles9

Excellent Outcomes
Our Full MagLev Flow Technology drives the same market-leading Heartmate 3™ LVAD with excellent clinical outcomes10

*PMA approval for 30-day use of CentriMag™ System excludes: PediMag™ Blood Pump and any other pediatric components or accessories.
**As part of a VA-ECMO circuit
***ECMO clearance for >6-hour use is indicated for the CentriMag™ Blood Pump to be used with: CentriMag™ Console, CentriMag™ Motor, Mag Monitor, and Flow Probe. ECMO clearance for the CentriMag™ Blood Pump is for adult use only and excludes: CentriMag™ Drainage Cannula and CentriMag™ Return Cannula.

 

References

  1. Takeda K, Garan AR, Ando M, et al. Minimally invasive CentriMag ventricular assist device support integrated with extracorporeal membrane oxygenation in cardiogenic shock patients: a comparison with conventional CentriMag biventricular support configuration. Eur J Cardiothorac Surg. 2017;52:1055–61.
  2. Worku B, Pak S, Patten D, et al. The CentriMag ventricular assist device in acute heart failure refractory to medical management. J Heart Lung Transplant. 2012;31:611–7.
  3. Takayama H, Soni L, Kalesan B, et al. Bridge-to-decision therapy with a continuous-flow external ventricular assist device in refractory cardiogenic shock of various causes. Circ Heart Fail. 2014;7;799-806.
  4. den Uil CA, Akin S, Jewbali LS, et al. Short-term mechanical circulatory support as a bridge to durable left ventricular assist device implantation in refractory cardiogenic shock: a systematic review and meta-analysis. Eur J Cardiothorac Surg. 2017;52:14–25.
  5. John R, Massey HT, Griffith BP, et al. Outcomes of a multicenter trial of the Levitronix CentriMag ventricular assist system for short-term circulatory support. J Thoracic Cardiovasc Surg. 2011;141:932-939.
  6. John R, Liao K, Lietz K, et al. Experience with the Levitronix CentriMag circulatory support system as a bridge to decision in patients with refractory acute cardiogenic shock and multisystem organ failure. J Thorac Cardiovasc Surg. 2007;134:351-358.
  7. Aziz TA, Singh G, Popjes E, et al. Initial experience with CentriMag extracorporeal membrane oxygenation for support of critically ill patients with refractory cardiogenic shock. J Heart Lung Transplant. 2010;29:66-71.
  8. Bhama JK, Kormos RL, Toyoda Y, et al. Clinical experience using the Levitronix CentriMag system for temporary right ventricular mechanical circulatory support. J Heart Lung Transplant. 2009;28:971-976.
  9. Data on file. Abbott; 2019.
  10. Mehra M, Uriel N, Naka Y, et al. A Fully Magnetically Levitated Ventricular Assist Device-Final Report. N Engl J Med. 2019;380:1618-1627.

Indications, Safety and Warnings

CentriMag Acute Circulatory Support System

HeartMate 3 LVAD

Indications, Safety & Warnings

MAT-2012740 v1.0

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

False
accessibility
© 2021 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

YESNO
accessibility

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

YESNO
accessibility
© 2021 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

YESNO
accessibility

Precautions


Please be sure to read it.

The following pages are intended for medical professionals and provide information on the proper use of products (medical devices, etc.) of Abbott Medical Japan GK.

The information provided here is not intended to provide information to patients and the general public.



Are you a healthcare professional?

 

Test

yesno